Outlook Therapeutics, Inc. Common Stock OTLK
$0.73
-1.35%
at last close
Market Cap$89.44 million
P/E Ratio—
Div Yield—
Volume31.62M
52-Week Range
$0.16$3.39
Key Stats
- Today's Range
- $0.68 – $0.82
- 50-Day Range
- $0.16 – $0.82
- 52-Week Range
- $0.16 – $3.39
- Volume
- 31.62 million shs
- Average Volume
- 23.85 million shs
- Market Cap
- $89.44 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.44
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.